Printer Friendly
The Free Library
19,607,050 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

FDA Panel Does Not Recommend Approval of Sunrise LTK System for Treatment of Low to Moderate Hyperopia at This Time.


FREMONT, Calif.--(BUSINESS WIRE)--July 22, 1999--

Sunrise Technologies Prepared to Work Closely With FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 to Pursue

Approval of LTK System

Sunrise Technologies International, Inc. (NASDAQ/NM:SNRS SNRS Securing Networks with Cisco Routers and Switches
SNRS Southern Nursing Research Society
) today announced that it will continue to pursue U.S. Food and Drug Administration (FDA) approval of the Company's Sunrise LTK (Laser Thermal Keratoplasty keratoplasty /ker·a·to·plas·ty/ (ker´ah-to-plas?te) plastic surgery of the cornea; corneal transplantation.

optic keratoplasty
) System for the treatment of low to moderate hyperopia (farsightedness). The announcement followed today's vote by the Ophthalmic Devices Panel, an advisory committee of the U.S. Food and Drug Administration (FDA), to not recommend that the FDA approve the Sunrise LTK System at this time.

"We will continue to work with the FDA to respond to the recommendations and issues presented by the Panel and to pursue approval of the Sunrise LTK System," said C. Russell Trenary III, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Sunrise Technologies.

Sunrise is seeking approval to market its Sunrise LTK System in the U.S. for the treatment of low to moderate hyperopia (farsightedness). The Sunrise LTK System is being successfully used in Europe, Africa, the Middle East, and the Americas.

"While we are of course disappointed with the Panel's vote, we continue to be cautiously optimistic that we will ultimately obtain approval from the FDA, which may or may not accept the Panel's recommendation," noted Mr. Trenary.

According to Jeannie G. Cecka, the Company's Vice President of Clinical and Regulatory Affairs, 656 cases were submitted in the Company's Premarket Approval Application (PMA PMA (papillary-marginal-attached),
n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation.

PMA Progressive muscular atrophy
) in the U.S., and the results met or exceeded target endpoints set by the FDA in its existing guidance pronouncements, with no reported sight-threatening complications or adverse reactions. However, the Panel suggested other criteria might be appropriate for discussion, including more long-term data. Sunrise was also the first Company ever to receive permission from the FDA for laser treatment of both eyes on the same day during a clinical trial.

Said Mr. Trenary, "Our clinical experience suggests that the Sunrise LTK System has the potential to `turn back the clock' and mimic the vision a patient had 10 or 20 years before. We believe that the Sunrise LTK System offers the potential for a safe, fast, and effective way to improve the vision of people with hyperopia, which occurs in many individuals as they reach age 40. At that point, people who may have never had vision problems may notice that they are having difficulty reading a restaurant menu and also reading signs along the highway."

The Sunrise LTK System Difference

The Sunrise LTK System uses a holmium holmium (hōl`mēəm) [Lat.,=Stockholm], metallic chemical element; symbol Ho; at. no. 67; at. wt. 164.9304; m.p. about 1,474°C;; b.p. about 2,425°C;; sp. gr. 8.78 at 25°C;; valence +3. :YAG laser that incorporates a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive conditions. The Sunrise LTK System uses gentle heat to reshape and steepen steep·en  
tr. & intr.v. steep·ened, steep·en·ing, steep·ens
To make or become steep or steeper.


steepen
Verb

to become or cause (something) to become steep or steeper

 the cornea without touching the eye with instrumentation.

It differs from excimer laser procedures such as Photorefractive Keratectomy (PRK PRK photorefractive keratectomy.
Photorefractive keratectomy (PRK)
A procedure that uses an excimer laser to make modifications to the cornea and permanently correct myopia.
), Laser-Assisted Instrastromal In Situ Keratomileusis keratomileusis /ker·a·to·mi·leu·sis/ (ker?ah-to-mi-loo´sis) keratoplasty in which a slice of the patient's cornea is removed, shaped to the desired curvature, and then sutured back on the remaining cornea to correct optical error.  (LASIK LASIK laser-assisted in-situ keratomileusis.

LA·SIK
n.
Eye surgery in which the surface of the cornea is reshaped using a laser, performed to correct certain refractive disorders such as myopia.
), and traditional incisional surgeries such as Radial Keratotomy (RK) because no incisions or laser ablations are used to cut or irretrievably ir·re·triev·a·ble  
adj.
Difficult or impossible to retrieve or recover: Once the ring fell down the drain, it was irretrievable.



ir
 remove corneal tissue; and from Intra Corneal Ring (ICR) and Intraocular Lens (IOL IOL Intraocular lens, see there ) procedures because nothing is inserted into the eye.

Founded in 1987, Sunrise Technologies International, Inc. is headquartered in Fremont, California, and develops, manufactures and markets patented holmium:YAG laser systems for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive conditions for applications in ophthalmology in the U.S., Europe, Africa, the Middle East, and the Americas.

The Company is focused on revolutionizing the treatment of hyperopia by bringing to market an in-the-office, effective, economical and elegant means of treating a refractive condition that is frustrating to patients. Since mid-1996, the Company has dedicated a significant portion of its efforts to engineering and development of the Sunrise LTK (Laser Thermal Keratoplasty) System for the treatment of refractive errors of the eye, such as hyperopia (farsightedness) and presbyopia Presbyopia Definition

The term presbyopia means "old eye" and is a vision condition involving the loss of the eye's ability to focus on close objects.
 (age-related loss of near-focusing ability).

Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgment, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements.

Caution: Investigational device. Federal law restricts this device to investigational use in the U.S.

Internet users can access Sunrise's World Wide Web site at http://www.sunrise-tech.com.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 23, 1999
Words:756
Previous Article:Presenting Solutions Inc. Skills-Evaluation Software Receives International Award.
Next Article:Sunrise Technologies International, Inc. Conference Call to be Broadcast Over the Internet.
Topics:



Related Articles
Sunrise Technologies Completes Enrollment of Patients in Phase III Primary Hyperopia Study.
Leading Ophthalmologist and Wife Treated With Sunrise LTK; Sunrise Plans 1998 Submission for Hyperopia PMA.
Sunrise Technologies International, Inc. Approved for Nasdaq National Market System Trading.
Sunrise Technologies International, Inc. Announces $10 Million Private Placement.
Sunrise Technologies International, Inc. Premarket Approval Application -PMA- Accepted for Filing by U.S. Food & Drug Administration.
Sunrise Technologies International, Inc. Receives Approval to Expand Study for Mid-Hyperopia.
Approval of Sunrise Hyperion LTK System Recommended By FDA Ophthalmic Devices Panel for Treatment of Low to Moderate Hyperopia With Conditions.
Sunrise Technologies International, Inc. Receives Approval to Place the HYPERION LTK System in Clinical Investigation Sites.
Sunrise Technologies' ASCRS Activities Generate Excellent Attendance as Company Seeks Final FDA Approval for HYPERION LTK System.
ONE IDEA.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles